ED
TCO

Exane Derivatives’s Taubman Centers Inc. TCO Stock Holding History

Exane Derivatives’s Portfolio TCO Stock Details TCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,515
Closed -$409K – 661
2016
Q2 		$409K Buy
+5,515
New +$388K 0.07% 147

Other funds holding TCO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAMU
APG Asset Management US New York $13B AUM 5.3% 1-Year Est. Return
LIMS
Lasalle Investment Management Securities Baltimore, Maryland $2.53B AUM 2.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPC
Long Pond Capital New York $1.05B AUM 16.49% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Exane Derivatives's TCO Position: Q3 2016 in Review

Exane Derivatives sold out of Taubman Centers Inc. (TCO) in Q3 2016, closing a stake of 5,515 shares — an estimated $409K sold.

Exane Derivatives first reported a position in TCO in Q2 2016 and held it in 1 quarter. The position peaked at $409K in Q2 2016. 250 funds tracked by Wall St. Rank hold TCO as of Q3 2016.

  • Exane Derivatives reported no remaining Taubman Centers Inc. position as of Q3 2016 after selling out during the quarter.
  • Exane Derivatives sold 5,515 Taubman Centers Inc. shares in Q3 2016, an estimated $409K.
  • Exane Derivatives first reported a position in Taubman Centers Inc. in Q2 2016 and held it in 1 quarter.
  • Exane Derivatives's Taubman Centers Inc. position peaked at $409K in Q2 2016.
  • 250 funds tracked by Wall St. Rank held Taubman Centers Inc. as of Q3 2016.

Based on Exane Derivatives's 13F filing for Q3 2016, filed 26 Oct 2016.